Sinopharm! An Unavoidable Contender in the Struggle Against COVID [Letter]

“Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety” [Response To Letter]

“…We read with interest the comments by Syed Hasan Shuja et al 1 regarding our article on the characteristics of the most common vaccines against COVID-19. 2 …”

“…2 In the present letter the authors underlined that in our review the vaccine by Sinopharm has not been mentioned which could possibly create panic and confusion in those people who were being given this vaccine in their vaccinal programs. 1 We are very sorry for this involuntary misunderstanding. However, we must specify that this review was submitted to the journal at the end of April 2021, the corrected version after the comments of the reviewers was sent in June, the acceptance by the editor occurred in July followed by the publication on August 31, 2021.…”

COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation—A Single-Center Study

“…The Pfizer BioNTech (BNT162b2) vaccine uses an mRNA that codes for the spike proteins, helping the host cell to create proteins similar to the SARS-CoV-2 spike proteins that activate immune cells and antibodies against these proteins, resulting in a competent immunity against the actual spikes of the virus [17]. The "BBIBP-CorV" vaccine is an inactivated virus that introduces the deadly virus to the body, allowing the immune system to recognize and activate the immune system without infecting the host cells [18].…”